Clinical trial NCT04325737: Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia
Official title: A Randomized, Double-blind, Placebo-controlled, Multiple Oral Dose Study Assessing the Safety and Tolerability of SEP-363856 in Japanese Subjects With Schizophrenia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Schizophrenia
Lead sponsor: Sumitomo Pharma Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2020-03-30
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multiple oral dose, randomized, double-blind, placebo-controlled study assessing the safety, tolerability and pharmacokinetics (PK) of SEP-363856 when administered qhs to Japanese subjects with schizophrenia.

Detailed description: This multicenter study will be conducted in 2 cohorts (Cohort 1 and 2). Cohort transition will be determined by the Safety Review Team (SRT) before the start of Cohort 2.

For each cohort, the target number of subjects completing the treatment period is defined as 8 for SEP-363856 group and 4 for placebo group. Subjects will be randomly assigned to either group. Dosing of the SEP-363856 group in Cohort 1 will be initiated at 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days. The SEP-363856 group in Cohort 2 will be dosed at 25 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days. In the placebo group, placebo will be orally administered according to the same administration schedule as the SEP-363856 group in each cohort.

Eligibility criteria: Inclusion Criteria:

1. Subjects who voluntarily provide written consent to participate in the study. If the subject is considered a minor at the time of collection of the informed consent, written consent will be obtained from a legally acceptable representative (guardian) in addition to that obtained from the subject.
2. Subject who has schizophrenia diagnosed by DSM-5, diagnostic criteria, and in the opinion of the Investigator has been clinically stable.
3. Subject who has body weight \>= 40.0kg and body mass index (BMI) \>= 18.5.
4. Female subjects who are premenopausal and of childbearing potential must have a negative serum pregnancy test result.
5. Female subjects who are of childbearing potential and male subjects whose partners are of childbearing potential must agree to use adequate and reliable contraception.

other

Exclusion Criteria:

1. Subjects who experienced an acute exacerbation of psychosis requiring change in antipsychotic medication (with reference to drug or dose) within 90 days before screening.
2. Subjects who become strongly affected by potent central nervous system depressants (including barbiturate) as considered by the Investigator.
3. Subjects who have any clinically significant unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study.
4. Subjects with active suicidal ideation or those with a suicide attempt history.
5. Subjects with a history or complication(s) of hypersensitivity to any medication.
6. Subjects with a history or complication(s) of malignant tumor within 5 years before screening, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. Pituitary tumors of any duration are excluded.
7. Subjects who have previous or existing infection with human immunodeficiency virus (HIV) at screening.
8. Subjects who have a positive syphilis serological test, Hepatitis B virus surface (HBs) antigen or Hepatitis C virus (HCV) antibody at screening.

other

Primary outcomes:
measure: Frequency of AEs, serious adverse events (SAEs), and AEs resulting in study discontinuation
timeFrame: 18 days
measure: Frequency of AEs, serious adverse events (SAEs), and AEs resulting in study discontinuation
timeFrame: 21 days
Secondary outcomes:
measure: Plasma concentrations of SEP-363856 and its metabolite SEP-363854
timeFrame: 18 days
measure: Plasma concentrations of SEP-363856 and its metabolite SEP-363854
timeFrame: 21 days
Other outcomes:
Locations:
city: Omuta-shi
country: Japan
facility: Shiranui Hospital
state: Fukuoka-Ken
city: Osaka-Fu
country: Japan
facility: Nishiurakai Keihan Hospital
state: Moriguchi-shi
city: Ueda-shi
country: Japan
facility: Mental Support SOYOKAZE Hospital
state: Nagano-Ken
city: Kunigami-gun
country: Japan
facility: NHO Ryukyu Hospital
state: Okinawa-Ken
city: Kanzaki
country: Japan
facility: NHO Hizen Psychiatric Center
state: Saga-Ken
city: Karatsu-shi
country: Japan
facility: Rainbow & Sea Hospital
state: Saga-Ken
city: Tosu
country: Japan
facility: Inuo Mental Care Hospital
state: Saga
city: Fukuoka
country: Japan
facility: Kuramitsu Hospital
Study officials:
References: